Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Spinocerebellar Degenerations 1 Rectal Neoplasms 1 Neoplasms 1 Locally Advanced Solid Tumor 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Fluorouracil 21 Oxaliplatin 17 Leucovorin 17 Bevacizumab 17 Irinotecan 13 Panitumumab 12 Cetuximab 12 IFL protocol 9 Capecitabine 9 pembrolizumab 7 Radiotherapy 7 Pemetrexed 5 Gemcitabine 5 labetuzumab 3 conatumumab 3 Cisplatin 3 Carboplatin 3 Albumin-Bound Paclitaxel 3 5,11-methenyltetrahydrohomofolate 3 130-nm albumin-bound paclitaxel 3 vatalanib 2 trametinib 2 spartalizumab 2 pegfilgrastim 2 ganitumab 2 encorafenib 2 dostarlimab 2 Ramucirumab 2 Paclitaxel 2 Melphalan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Rectal Neoplasms × E7046 × Clear all

NCT03152370 2021-10-04

PRAER 1

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Completed

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡